# FDA Approves Glenmark Pharmaceuticals' Generic Olanzapine Injection, Expanding Long-Acting Antipsychotic Market The FDA has approved Glenmark Pharmaceuticals Inc.'s abbreviated new drug application for generic olanzapine intramuscular injection, potentially allowing the company to capture market share in the long-acting antipsychotic segment as patent protections for branded formulations continue to erode. The approval could increase price competition and improve patient access to this widely-prescribed treatment for schizophrenia and bipolar disorder.